The Relative Strength (RS) Rating for Alnylam Pharmaceuticals climbed into a new percentile Friday, as it got a lift from 69 to 76.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an RS Rating of at least 80 as they launch their largest climbs. See if Alnylam Pharmaceuticals can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a consolidation and break out.
The company showed 0% earnings growth in its most recent report, while sales growth came in at -33%. Look for the next report on or around Feb. 6.
Alnylam Pharmaceuticals holds the No. 150 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and ADMA Biologics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
